One factor that may contribute to the increase in criminal antitrust fines over the past ten years is the Antitrust Division's international focus.

Today the Seventh Circuit Court of Appeals hears oral argument from the parties and amicus curiae the United States concerning the reach of the FTAIA, 15 U.S.C. § 6a, in Motorola Mobility LLC v. AU Optronics.

Yesterday, the FTC announced that it reached a settlement in its pay-for-delay lawsuit, FTC v. Cephalon Inc. in the U.S. District Court for the Eastern District of Pennsylvania, with Teva Pharmaceuticals Industries, Ltd., which acquired Cephalon in 2012.

Since the first social impact bond financing was launched in the United Kingdom in 2010, more and more attention is being directed to pay-for-success (or social impact) financing, both domestically and abroad.

Nonetheless, in its Answer with Counterlcaims Apotex alleged that Amgen engaged in sham litigation by including the '138 patent in its complaint against Apotex.

AbbVie's Humira is a blockbuster treatment for rheumatoid arthritis.

In the past year, the Tax Exempt and Government Entities Division of the Internal Revenue Service has been engulfed in controversy, resulting in sweeping changes in both its personnel and operations.

Yesterday, the Ninth Circuit issued an opinion affirming the dismissal of plaintiffs' consolidated complaint in In re Musical Instruments and Equipment Antitrust Litigation.

We have previously posted about the New York Attorney General's "product hopping" suit against Actavis and its subsidiary, Forest Laboratories LLC.

A few tax considerations are at play if one is donating an interest in a GP or management company, warn tax experts Dahlia Doumar and Carl Merino.

It is also critical to develop a plan for responding to a cyberattack or data breach before it happens.

In a short per curiam opinion in United States v. Lobo (Parker, Hall, Lohier), the Second Circuit affirmed the imposition of a Guidelines enhancement based on the importation of a controlled substance into the United States.

Hospira's proposed biosimilar has not been licensed by FDA.

This morning, the full Federal Circuit declined to rehear en banc Amgen v. Sandoz, the first appellate decision interpreting the Biologics Price Competition and Innovation Act of 2009 (BPCIA).

The issues raised in Hospira's motion to dismiss are currently before the Federal Circuit in Amgen's and Sandoz's petitions for rehearing en banc.

In Amgen v. Apotex, Judge Cohn of the Southern District of Florida recently enjoined Apotex from selling its proposed biosimilar of Amgen's Neulasta for 180 days following FDA approval.

Bankruptcy plans often include provisions releasing debtors and their officers and directors from certain potential liability.

On September 5, 2018, Chief United States District Judge Colleen McMahon (S.D.N.Y.) issued a decision denying Plaintiff GeigTech's motion for preliminary injunction in its patent and trade dress infringement suit against Defendant Lutron.

As we previously reported, Capital One Financial Corporation announced in July 2019 a major data security breach when an individual gained unauthorized access to personal information about Capital One credit card customers.

In Accenture's 2018 State of Cyber Resilience for Banking & Capital Markets study, the consulting firm reported the rate at which cyber-attacks on banking and capital markets firms are successful dropped from 36 percent in 2017 to 15 percent in 2018.